SVB Leerink

Galecto to Participate at Upcoming Investor Conferences

Retrieved on: 
Monday, February 7, 2022

A live webcast of the presentation at SVB Leerink will be available on the "News & Events" section of Galectos Investor website at https://ir.galecto.com/news-and-events/events .

Key Points: 
  • A live webcast of the presentation at SVB Leerink will be available on the "News & Events" section of Galectos Investor website at https://ir.galecto.com/news-and-events/events .
  • A replay of the presentation will be available on this same website following the event.
  • Galecto is a clinical stage company incorporated in the U.S. that is developing small molecule-based inhibitors of galectin-3 (and the galectin family generally) and LOXL2.
  • Galecto intends to use its website as a means of disclosing material non-public information.

Daré Bioscience to Participate in Upcoming Conferences

Retrieved on: 
Monday, February 7, 2022

Dar Bioscience is a biopharmaceutical company committed to advancing innovative products for womens health.

Key Points: 
  • Dar Bioscience is a biopharmaceutical company committed to advancing innovative products for womens health.
  • The information Dar posts on its investor relations website or through social media channels may be deemed to be material information.
  • Dar encourages investors, the media, and others interested in the company to review the information Dar posts in the Investors section of its website and to follow these Twitter accounts: @SabrinaDareCEO and @DareBioscience.
  • Investors on behalf of Dar Bioscience, Inc.:

Cullinan Oncology to Present at SVB Leerink’s 11th Annual Global Healthcare Conference

Retrieved on: 
Monday, February 7, 2022

CAMBRIDGE, Mass., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (Cullinan) today announced that it will be participating in SVB Leerinks 11th Annual Global Healthcare Conference, being held virtually February 14-18, 2022.

Key Points: 
  • CAMBRIDGE, Mass., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (Cullinan) today announced that it will be participating in SVB Leerinks 11th Annual Global Healthcare Conference, being held virtually February 14-18, 2022.
  • Nadim Ahmed, Cullinans Chief Executive Officer, will participate in a fireside chat on Thursday, February 17th at 8:40 a.m.
  • ET
    A live webcast of the fireside chat will be available via the Events section of the Companys investor relations website at https://investors.cullinanoncology.com/news-events/events .
  • Cullinan Oncology is a biopharmaceutical company that is developing a diversified pipeline of targeted therapeutic candidates across multiple modalities in order to bring important medicines to cancer patients.

GenNx360 Capital Partners Announces Investment in Nutra-Med Packaging, Inc.

Retrieved on: 
Friday, February 4, 2022

Nutra-Med is a Whippany, New Jersey-based contract packaging company focused on packaging for the Pharmaceutical, Health & Wellness and Medical Devices markets.

Key Points: 
  • Nutra-Med is a Whippany, New Jersey-based contract packaging company focused on packaging for the Pharmaceutical, Health & Wellness and Medical Devices markets.
  • Mahesh Gupta, the founder of Nutra-Med, will continue to serve in an advisory role to the Company.
  • "GenNx360 Capital Partners' Fund III enters 2022 with great momentum led by its investment in Nutra-Med, Fund III's 6th platform investment.
  • GenNx360 Capital Partners is a private equity firm focused on acquiring middle market industrial and business services companies.

Arcellx Announces Pricing of Initial Public Offering

Retrieved on: 
Friday, February 4, 2022

GAITHERSBURG, Md., Feb. 04, 2022 (GLOBE NEWSWIRE) -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the pricing of its initial public offering of 8,250,000 shares of common stock at a public offering price of $15.00 per share.

Key Points: 
  • GAITHERSBURG, Md., Feb. 04, 2022 (GLOBE NEWSWIRE) -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the pricing of its initial public offering of 8,250,000 shares of common stock at a public offering price of $15.00 per share.
  • The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Arcellx, are expected to be approximately $123.8 million.
  • In addition, Arcellx has granted the underwriters a 30-day option to purchase up to an additional 1,237,500 shares of common stock at the initial public offering price, less underwriting discounts and commissions.
  • The offering is expected to close on February 8, 2022, subject to the satisfaction of customary closing conditions.

Aligos Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

Retrieved on: 
Thursday, February 3, 2022

An audio webcast of the presentation will be available using the webcast registration link or through the Aligos investor section of the website.

Key Points: 
  • An audio webcast of the presentation will be available using the webcast registration link or through the Aligos investor section of the website.
  • https://investor.aligos.com
    The Aligos management team will also participate in investor 1x1 meetings during the conference.
  • Please contact your SVB Leerink representative to schedule virtual one-on-one meetings with Aligos during the conference.
  • For more information about the 11th Annual SVB Leerink Global Healthcare Conference, please refer to the Events Website .

Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences

Retrieved on: 
Thursday, February 3, 2022

NEW YORK and SAN DIEGO, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that Anthony Sun, MD, Chairman and Chief Executive Officer of Zentalis, will participate in fireside chats at two upcoming virtual investor conferences.

Key Points: 
  • NEW YORK and SAN DIEGO, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that Anthony Sun, MD, Chairman and Chief Executive Officer of Zentalis, will participate in fireside chats at two upcoming virtual investor conferences.
  • Following the events, archived webcasts will be available on the Zentalis website.
  • Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers.
  • Zentalis has licensed ZN-c3, ZN-c5 and ZN-d5 to its joint venture, Zentera Therapeutics, to develop and commercialize these candidates in China.

SomaLogic to Participate in Upcoming Investor Conferences

Retrieved on: 
Wednesday, February 2, 2022

BOULDER, Colo., Feb. 02, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced that the company will be participating in the following virtual investor conferences.

Key Points: 
  • BOULDER, Colo., Feb. 02, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced that the company will be participating in the following virtual investor conferences.
  • ET
    Interested parties may access a live and archived webcast of the SVB Leerink virtual session on the Investors section of the companys website at: https://investors.somalogic.com/events-and-presentations .
  • SomaLogic (Nasdaq: SLGC) seeks to deliver precise, meaningful, and actionable health-management information that empowers individuals worldwide to continuously optimize their personal health and wellness throughout their lives.
  • For more information, visit www.somalogic.com and follow @somalogic on Twitter.

Edgewise Therapeutics to Participate at SVB Leerink 11th Annual Global Healthcare Conference on February 16

Retrieved on: 
Wednesday, February 2, 2022

Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatment of rare muscle disorders, announced today that members of its senior management team will participate in a fireside discussion and one-on-one investor meetings at the SVB Leerink Virtual 11th Annual Global Healthcare Conference, on February 16, 2022.

Key Points: 
  • Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatment of rare muscle disorders, announced today that members of its senior management team will participate in a fireside discussion and one-on-one investor meetings at the SVB Leerink Virtual 11th Annual Global Healthcare Conference, on February 16, 2022.
  • The fireside chat will be webcast live on February 16 at 12 pm ET; a link for the webcast can be found on the Edgewise events page and will be accessible for replay following the presentation.
  • It is recommended that users connect to the webcast several minutes prior to the start to ensure a timely connection.
  • Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare neuromuscular and cardiac disorders for which there is significant unmet medical need.

Aclaris Therapeutics to Participate in the SVB Leerink Virtual 11th Annual Global Healthcare Conference

Retrieved on: 
Wednesday, February 2, 2022

WAYNE, Pa., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, President and CEO of Aclaris, will participate in a fireside chat at the SVB Leerink Virtual 11th Annual Global Healthcare Conference on Wednesday, February 16, 2022 at 9:20 a.m.

Key Points: 
  • WAYNE, Pa., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, President and CEO of Aclaris, will participate in a fireside chat at the SVB Leerink Virtual 11th Annual Global Healthcare Conference on Wednesday, February 16, 2022 at 9:20 a.m.
  • Management will be available February 16th throughout the day for virtual 1x1 meetings.
  • A webcast of the fireside chat may be accessed through the Events page of the Investors section of Aclaris website, www.aclaristx.com.
  • Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options.